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Acute respiratory distress syndrome is a heterogeneous clinical condition 
characterised by complex pathophysiological mechanisms such as dysregulated pulmonary 
and systemic inflammation, diffuse alveolar epithelial and endothelial cell injury and altered 
alveolar membrane permeability (1, 2). ARDS remains common (3) with high mortality of 48% 
(45% - 51%) in observational studies and 37% (34% - 41%) in clinical trials (4). There are no 
pathognomonic signs or diagnostic tests for ARDS (5). For diagnosis at the bedside, the 
ARDS definition identifies clinical phenotypes with predictive validity categories based on the 
severity of hypoxaemia to supplement clinical judgement and radiological findings. However 
due to the underlying biological differences within the overall clinical phenotype, these 
categories do not necessarily equate to generic treatment responses and interventions may 
only be effective in a sub-population of the overall cohort of patients with ARDS in a 
randomised clinical trial (RCT) (1). Therefore whether it is possible to identify these ARDS 
treatment response groups is an important question.  
ARDS phenotype subsets (subphenotypes) represent patient groups within a 
heterogeneous ARDS cohort with a similar set of observable clinical, radiological, biological 
and/or outcome characteristics. ARDS endo-phenotypes (endotypes) represent patient 
subsets of ARDS defined either by a biologically restricted molecular pathway/mechanisms or 
by differences in treatment response or rarely both. Our current understanding of causal 
determinants (6) of clinical, radiological and biological manifestations, treatment responses, 
outcomes and their inter relationships is incomplete. ARDS literature like the sepsis literature 
is replete with RCTs where there are no differences in the average treatment effect between 
the intervention and control arms. Identifying ARDS subgroups with either an improved 
average treatment effect or a decreased variation in treatment response or a greater event 
rate or combinations thereof, may make it possible to reduce the probability of trials that show 
no statistically significant difference in average treatment effect (7). Reanalysis of data from 
completed RCTs with an emphasis on identifying these subgroups within the ARDS 
phenotype-endotype continuum represents a novel approach. 
Latent class analysis (LCA), highlighted Lazarsfeld by in the 1950s (8), is one 
approach to identify clustering within cohorts, by testing the hypothesis that two or more 
unobserved categories (latent classes) explain the relationships between observed variables 
in the cohort. The primary goal of LCA is to identify the most parsimonious set of predictor 
variables and latent classes that explain the cohort data. LCA assumes that all data points 
have conditional independence and come from one of these unobserved categories. The 
granularity of data is reduced to standard normal distribution for analysis. The choice of 
variables, the model characteristics and the number of latent classes are dependent on the 
methods used (9-11). Therefore LCA could potentially identify these ARDS subgroups. 
Using LCA of data from the ARMA and ALVEOLI RCTs in ARDS, Calfee and 
colleagues previously reported two ARDS subgroups with distinct clinical, biological and 
outcome characteristics with one subgroup characterised by a higher prevalence of shock, 
greater inflammation and endothelial injury and higher mortality (12). Significant interaction 
between the subphenotype and response to PEEP was also identified. In this issue, Famous 
K et al replicate these findings using data from the FACTT trial(13). They show that the two-
class LCA model, with one group again characterized by hypotension, inflammation and 
mortality still holds true. Significant interaction between the subphenotypes and fluid regimen 
was also observed. 
This important body of work represents the beginning of personalised medicine for 
ARDS by improving our understanding of disease mechanisms, treatment response 
characteristics, and outcome determinants. This work could allow researchers to delineate 
causal mechanistic pathways in the development of ARDS, which could help tailor treatment 
accounting for individual heterogeneity. The ability to identify patient cohorts who are more 
likely to respond to a specific therapy (predictive enrichment)(14) could represent a major 
advance in clinical trial design in ARDS. Several additional questions remain. First, data to 
support these ARDS subgroups are limited to the specific population recruited into ARDSnet 
RCTs. Thus it would be useful to replicate and validate these findings in ARDS population 
from other international RCTs and whether these ARDS subgroups could be identified within 
unselected observational cohorts. Second, it is important to know if a patient’s ARDS 
subgroup allocation changes over time as this could have implications for the timing of 
interventions. Finally it is important to highlight that caution is required with causal and 
treatment response inferences as the premise of randomisation may no longer be valid in 
these analyses. This last point that is perhaps the most fundamental challenge, is best 
addressed in clinical trials designed to specifically test the hypothesis that these ARDS 
endotypes can be identified prior to randomisation and are associated with an increased 
likelihood of a positive treatment response (statistically significant average treatment effect). 
Such trials will be enabled by the development of point of care assays for recognition of 
ARDS endotypes in real-time. In terms of the current work, these data also raise the potential 
the need to re-visit fluid therapy in ARDS patients.  
What are the implications of this research going forward? The authors have shown 
unequivocally that there is an urgent need for further research to understand these ARDS 
subgroups within the complex phenotype-endotype continuum and to establish uniform 
reporting standards. Calfee and colleagues(12, 13) have done an excellent service to our 
speciality by highlighting a fresh approach to study patient heterogeneity, which is likely to 
both improve our understanding of the pathophysiology of ARDS as well as inform future 
trials in ARDS as a new era of personalised medicine for ARDS emerges.  
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